Frequently Asked Questions

You may be a candidate if you have a BMI of 30 or higher, or a BMI of 27+ with a weight-related health condition such as type 2 diabetes, high blood pressure, or sleep apnea. Our board-certified physicians evaluate your complete medical history during a free telehealth consultation to determine eligibility. There is no obligation.

Everything happens online. You complete a medical intake form, have a video consultation with a licensed physician, receive a personalized treatment plan, and your medication ships directly to your door. Monthly check-ins, dose adjustments, and provider messaging are all virtual. We are licensed in all 50 states.

We prescribe GLP-1 medications receptor agonists including semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro/Zepbound). We also monitor emerging therapies like retatrutide (GLP-3), a next-generation triple agonist currently in Phase 3 trials. Your physician recommends the best option for your medical profile.

Most patients notice reduced appetite within the first week and measurable weight loss within 4-8 weeks. Clinical trials show 15-18% body weight reduction with semaglutide over 68 weeks, 18-22% with tirzepatide, and 24-30%+ with retatrutide. Individual results vary based on starting weight, adherence, and metabolic factors.

GLP-1 receptor agonists are physician-prescribed medications that mimic the incretin hormone GLP-1 to reduce appetite, slow gastric emptying, and improve blood sugar regulation. GLP-3 refers to retatrutide, a next-generation triple-agonist compound that targets GLP-1, GIP, and glucagon receptors simultaneously, producing weight loss exceeding 30% in clinical trials published in the New England Journal of Medicine.

Retatrutide is the first triple-agonist weight loss compound, targeting three receptors instead of one or two. The addition of glucagon receptor activation increases basal metabolic rate and promotes hepatic fat oxidation — mechanisms not available in semaglutide or tirzepatide. Phase 2 trial data shows 30%+ average body weight reduction, significantly exceeding current options.

The most common side effects are mild gastrointestinal symptoms — nausea, vomiting, diarrhea, and constipation — which typically subside within 2-4 weeks as your body adjusts. Our physicians use a gradual dose-escalation protocol to minimize these effects. Serious side effects are rare and monitored during regular check-ins.

Semaglutide (Wegovy) and tirzepatide (Zepbound) are for chronic weight management. Retatrutide (GLP-3) is currently investigational and in Phase 3 clinical trials — it has not yet received FDA approval. We clearly label investigational compounds on our site and only prescribe physician-prescribed medications.

Our plans start at $299/month for semaglutide (Essential plan), $399/month for tirzepatide (Advanced plan), and $499/month for our Elite GLP-3 program. Every plan includes the medication, physician consultations, dose management, 24/7 provider messaging, and free priority shipping. No hidden fees or long-term contracts.

We operate as a self-pay platform to keep pricing transparent and eliminate insurance delays. Our pricing is often comparable to or lower than insurance copays for branded GLP-1 medications. We provide itemized receipts that patients can submit for potential reimbursement through out-of-network benefits or HSA/FSA accounts.

After your physician approves your treatment plan, prescriptions are sent same-day to our licensed partner pharmacy. Most patients receive their medication within 48 hours via priority shipping at no additional cost. Medications arrive in temperature-controlled packaging to ensure potency.

Refills are shipped automatically before your current supply runs out — you never have gaps in treatment. Monthly check-ins with your physician ensure your dosing is optimized. You can message your provider anytime through our secure platform for questions between appointments.

Research shows that weight regain is possible after discontinuation, which is why our program includes nutrition guidance and behavioral support to build sustainable habits. Many patients transition to a maintenance protocol with lower doses. Your physician works with you to create a long-term strategy that extends beyond medication alone.

Exercise is not required for the medication to work — clinical trials demonstrated significant weight loss without mandatory exercise protocols. However, physical activity improves overall health outcomes, preserves lean muscle mass during weight loss, and supports long-term weight maintenance. Our physicians provide personalized guidance on activity levels.

Yes. If you are currently on a GLP-1 medication from another provider, our physicians can evaluate your current protocol and continue your treatment without interruption. We will need your recent lab work and medication history, which you can upload during the intake process.

We are fully HIPAA-compliant. All medical data is encrypted at rest and in transit using AES-256 encryption. We never sell or share patient data with third parties. Our telehealth platform uses end-to-end encrypted video and messaging. You can review our full privacy policy for details.